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Abstract
Earlier observations in the literature suggest that proteolytic degradation of excess unmatched a-globin chains reduces
their accumulation and precipitation in b-thalassaemia erythroid precursor cells and have linked this proteolytic degradation
to the activity of calpain protease. The aim of this study was to correlate the activity of calpain and its inhibitor, calpastatin,
with different degrees of disease severity in b-thalassaemia. CD34
+ cells were enriched from peripheral blood of healthy
individuals (control group) and patients with mild and severe clinical presentations of b
0-thalassaemia/Hb E disease. By ex
vivo cultivation promoting erythroid cell differentiation for 7 days, proerythroblasts, were employed for the functional
characterization of the calpain-calpastatin proteolytic system. In comparison to the control group, enzymatic activity and
protein amounts of m-calpain were found to be more than 3-fold increased in proerythroblasts from patients with mild
clinical symptoms, whereas no significant difference was observed in patients with severe clinical symptoms. Furthermore,
a 1.6-fold decrease of calpastatin activity and 3.2-fold accumulation of a 34 kDa calpain-mediated degradation product of
calpastatin were observed in patients with mild clinical symptoms. The increased activity of calpain may be involved in the
removal of excess a-globin chains contributing to a lower degree of disease severity in patients with mild clinical symptoms.
Citation: Sukati S, Svasti S, Stifanese R, Averna M, Panutdaporn N, et al. (2012) Clinical Severity of b-thalassaemia/Hb E Disease Is Associated with Differential
Activities of the Calpain-Calpastatin Proteolytic System. PLoS ONE 7(5): e37133. doi:10.1371/journal.pone.0037133
Editor: Tianqing Peng, University of Western Ontario, Canada
Received February 1, 2012; Accepted April 17, 2012; Published May 16, 2012
Copyright:  2012 Sukati et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was partially supported by a research team strengthening grant (‘‘Disease Modifier Genes in Thalassaemia’’) from the National Science and
Technology Development Agency of Thailand (NSTDA) under the BIOTEC subsection, the Office Of The Higher Education Commission and Mahidol University
under the National Research University Initiative, and in part by grants from Ministero dell’Istruzione dell’Universita e della Ricerca (PRIN 2008, to EM), and from
the University of Genoa, Italy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: frkgz@mahidol.ac.th
Introduction
Thalassaemia is an inherited disorder occurring with high
prevalence in Southeast Asia. In Thailand, a-thalassaemias attain
frequencies of up to 30% and b-thalassaemias vary from 3–9% in
different populations [1]. In severe cases of b-thalassaemia, the
accumulation and subsequent precipitation of excess unpaired a-
haemoglobin chains in red cell precursors causes a number of
pathological symptoms such as ineffective erythropoiesis, anaemia
and haemolysis which ultimately can result in skeletal abnormal-
ities and eventually organ damage such as cardiac failure [2].
Mutations in the b-globin gene can either lead to impaired
synthesis (b
+-thalassaemia) or complete absence (b
0-thalassaemia)
of b-globin chains [3] and polymorphisms in the b-globin cluster
leading to the disease phenotype have been extensively charac-
terized [4,5]. Hb E, one of the most common haemoglobin
variants with frequencies of up to 50% in the border region of
Laos, Cambodia and Thailand, displays a GRA substitution in
codon 26 of the b-globin gene (b
E). It is probably the most
common b-thalassaemia allele worldwide. Compound heterozy-
gotes with a coinherited deficiency in a second b-thalassaemia
allele leading to b
0-thalassaemia/Hb E disease, can demonstrate
a highly variable presentation of disease symptoms despite having
apparently identical genotypes. The remarkable variation of
disease severity can range from nearly asymptomatic (‘mild’ form)
to transfusion-dependent anaemia (‘severe’ form).
The major factor involved in the pathophysiology of b-
thalassaemia is probably the high amount and precipitation of
excess a-globin chains which leads to subsequent oxidative
damage of developing red cells. Among other inherent factors
that were proposed as possible modulators of disease severity were
elevated Hb F production, erythropoiesis and proteolysis in the
erythrocyte [6]. The latter was suspected to affect the severity of
thalassaemia by a reduction of the amount of excess a-globin
chains and thereby ameliorating the pathological effects of globin
chain imbalance to the cell [6]. Earlier observations in the
literature have demonstrated that the proteolytic processes in-
volved in haemoglobin breakdown entail pathways which are
dependent on ubiquitin, ATP and intracellular Ca
2+-ions [7,8].
Previous studies have used mature erythrocytes for the analysis
of proteolytic globin degradation [9,10], however, several reports
have suggested that globin breakdown is accelerated in the bone
marrow when compared to peripheral blood reticulocytes [11,12]
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cells is reflective of an ineffective erythropoiesis in severe cases of
b-thalassaemia [13]. Moreover, a number of reports published
later indicated that the activity of calpain and calpain activator
(CA) progressively decreases during the maturation and differen-
tiation of erythroid precursor cells [14,15]. We have therefore
decided to cultivate enriched CD34
+ precursor cells to the
proerythroblast stage and used for the analysis of calpain and
calpastatin activity.
With the aim to seek further confirmatory evidence for a role of
the calpain-calpastatin proteolytic system as modulator of disease
phenotypes in b
0-thalassaemia/Hb E patients, we have un-
dertaken a comparative biochemical analysis of calpain activity
in samples from patients with mild and severe symptoms. The
findings presented in this study support the view that activity of
calpain and its inhibitor, calpastatin, may be of functional
significance for the presentation of disease symptoms in b-
thalassaemia.
Materials and Methods
2.1 Ethics statement
The research described herein was carried out in full
compliance with the Helsinki declaration. Study design and
informed consent form for patients were approved by the
Committee on Human Rights Related to Human Experimenta-
tion of Mahidol University, Nakorn Pathom, 73170 Thailand
(reference number MU 2006-139,. File S1). Patients agreed to
participate in the study by signing a written consent form
translated into their native (Thai) language (File S2). No animals
were utilized in this study to produce recombinant calpastatin
from rat brain as described in an earlier publication [16].
2.2 Subjects
Thai/Chinese b
0-thalassaemia/Hb E patients were categorized
into groups with mild and severe clinical symptoms according to
a scoring system for the severity of b-thalassaemia/Hb E disease
[17]. Healthy volunteers were identified by using haemoglobin
typing (HPLC b-globin variant short program, Bio-Rad Labora-
tories, Hercules, CA, USA) and were recruited as control group.
Multiplex polymerase chain reaction was used to screen for
mutations in a-thalassaemia genes [18]. In order to reduce
possible genetic background effects, only b
0-thalassaemia/Hb E
disease patients carrying mutations in b
codon 41/42; 2TTCT and b
E
were selected for this study. Patients with co-inherited a-
thalassemia were excluded from the study and patients with mild
and severe symptoms had no significant differences in their Hb F
amounts (37.5761.78% and 37.5662.72%, respectively). Patients
did not receive blood transfusions for at least one month and
medication for at least 2 weeks prior to blood sample collection.
Subjects had no other health issues and were free of infections at
the time of sample collection.
2.3 Purification of CD34
+pheripheral blood mononuclear
cells (PBMC)
Peripheral blood (30 ml from b
0-thalassaemia/Hb E patients
and 50 ml from healthy controls) of peripheral venous blood were
collected in heparin (0.2 mg ml
21 blood) and PBMC were
obtained by centrifugation at 8006g for 20 min at room
temperature on Lymphoprep
TM (AXIS-SHIELD PoC AS, Oslo,
Norway). CD34
+ cells were selected from PBMC using anti-CD34
magnetic microbeads and magnetic activated cell sorting (MACS)
separation columns (both from Miltenyi Biotech, Auburn, CA,
USA) according to the manufacturer’s protocol.
2.4 Erythroid precursor cell culture
CD 34
+cells were grown under standard culture conditions [19].
Briefly, isolated peripheral CD34
+ cells were cultured in Iscove’s
Modified Dulbecco’s Media (IMDM; GIBCO BRL, Grand Island,
NY, USA) containing 1% deionized bovine serum albumin (Stem
Cell Technologies Inc. Vancouver, BC, Canada), 15% heat
inactivated foetal calf serum (FCS; GIBCO BRL), 15% human
serum type AB from healthy male donors, 100 U ml
21 penicillin,
and 100 U ml
21 streptomycin (GIBCO BRL) with the following
recombinant cytokines: 2 U ml
21 recombinant human erythro-
poietin (rhEPO; EPREX, Brussels, Belgium), 20 ng ml
21
recombinant human stem cell factor (rhSCF; Promokine, Heidel-
berg, Germany), and 10 ng ml
21 recombinant human interleukin-
3 (rhIL-3; Promokine), then incubated at 37uC under 5% CO2.
On day 3, cells were centrifuged at 4006g for 7 min at room
temperature and the collected cells were incubated under identical
conditions without rhIL-3. Cells were cultured for 7 days and used
for further experiments. Purity of erythroid cells was determined
by staining cells with erythroid specific-cell surface makers,
allophycocyanin (APC)-conjugated monoclonal mouse anti-hu-
man glycophorin A (CD235a) and phycoerythrin (PE)-conjugated
monoclonal mouse anti-human transferrin receptor (CD71) (BD
Bioscience, Pharmingen, San Diego, CA, USA). Stained cells were
analyzed by a flow cytometer (FACSCalibur, BD Biosciences, San
Jose, CA, USA). Signal areas (R1–R3) were gated for the detection
of glycophorin A (CD235a) and transferrin receptor (CD71). Cell
morphology was evaluated by cytospin preparation (Cytofuge 2,
Statspin, Inc., Norwood, MA, USA) for 5 min at 1,000 rpm
following staining with Wright-Giemsa dye. Cells were analyzed
by using differential counting with light microscopy (magnification
1000-fold) (Olympus CH-2, Olympus Optical Co. Ltd, Tokyo,
Japan).
2.5 Preparation of recombinant rat brain calpastatin
RNCAST300
Recombinant rat brain calpastatin RNCAST300, composed of
exon 8 and a single inhibitory unit (exons 9–12), has been
prepared, purified and assayed as described previously [16]. In
order to completely inhibit calpain activity, 10 nM (1.1 mgm l
21)
RNCAST300 was added to the cell lysates.
2.6 Determination of calpain activity
5610
6 cells were lysed in 500 ml of ice-cold hypotonic medium
50 mM sodium borate buffer, pH 7.5, containing 0.5 mM 2-
mercaptoethanol (buffer A) and 5 mM EDTA by three cycles of
freezing and thawing in liquid nitrogen. The particulate material
was separated by centrifugation at 100,0006g for 10 min at 4uC
and discarded. Cytosolic fractions were collected and utilized for
assay of calpain activity with the fluorogenic peptide substrate Ac-
LLY-afc (BioVision Inc., Mountain View, CA, USA) and of 1 mM
Ca
2+ over the EDTA present in the samples. As controls, the same
incubation mixtures were carried out in the presence of 5 mM
EDTA. The dependency of the detected proteolytic activity from
calpain was established by adding to the assay incubation mixtures
at a final concentration of 10 mM the irreversible calpain inhibitor
Z-LLY-fmk [20,21] or 1.1 mgm l
21 recombinant calpastatin form
RNCAST300 [16]. Fluorescence was detected on a spectrofluo-
rometer (Wallac 1420 Victor 2, Perkin Elmer, Wellesley, MA,
USA) at excitation wavelength l=400 nm and emission wave-
length l=505 nm. Calpain activity is calculated and reported
throughout the text on the basis of the difference between the
fluorescence values detected from the complete incubation
mixtures and the fluorescence values obtained with incubation
Calpain and beta-thalassaemia
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of the metabolism in cultured erythroid precursor cells were
excluded by determination of activity of glycerol aldehyde-3-
phosphate dehydrogenase (GAPDH) using the KDalert
TM
GAPDH Assay Kit (Ambion Inc., Austin, Texas, USA) according
to the manufacturer’s instructions. All assays were performed in
duplicate and numerical values are presented as mean plus or
minus standard error.
2.7 Western blot analysis
10
6 cells were lysed with 35 ml ice-cold lysis buffer (50 mM Tris-
HCl, pH 7.5, 15 mM NaCl, 1% triton X-100, 1 mM EDTA,
1 mM EGTA, 10 mM sodium b-glycerophosphate, 5 mM sodium
pyrophosphate, and protease inhibitor cocktail, Sigma-Aldrich).
Protein samples (10 mg) were run on 8% SDS-PAGE and
subsequently transferred to polyvinyl difluoride (PVDF) mem-
branes. Membranes were probed with mouse monoclonal anti-m-
calpain (large subunit) at 1:1,000 dilution (Chemicon International
Inc., San Diego, CA, USA) and a monoclonal mouse anti-
GAPDH antiserum (Santa Cruz Biotechnology Inc., Santa Cruz,
CA, USA) at 1:7,500 dilution. Alternatively, protein samples
(25 mg) were run on 6%–10% gradient SDS-PAGE and sub-
sequently transferred to PVDF membranes. Membranes were
probed with mouse monoclonal a-spectrin II antibody at 1:1,000
dilution (Chemicon) and anti-GAPDH (Santa Cruz Biotechnology
Inc.) at 1:10,000 dilution. Bands were visualized using horseradish
peroxidase conjugated anti-mouse IgG (GE Healthcare UK
limited, Buckinghamshire, England, dilution 1:5,000) with the
ECL plus Western blotting detection system (GE Healthcare).
Band intensities of proteins were analyzed by densitometric
scanning of the membrane and quantified using the ImageJ 1.41
program (National Institutes of Health, Bethesda, USA).
2.8 Determination of calpastatin activity
Calpastatin activity in cell lysates was analyzed by procedures
described previously in the literature [22]. 5610
7 erythroid
precursors cultured from 4 healthy controls, 5 patients with mild
and 5 patients with severe clinical symptoms, respectively, were
lysed in 625 ml of ice-cold buffer A containing 1 mM EDTA as
previously described. Cytosolic fractions, prepared as previously
described, were collected, heated for 3 min at 100uC, and
precipitated proteins were removed by centrifugation at
100,0006g for 10 min at 4uC. The supernatant was loaded onto
a diethylaminoethyl cellulose resin (DE53) anion exchange
chromatography column (165 cm) (Whatman, Hillsboro, OR,
USA) equilibrated with buffer A containing 0.1 mM EDTA.
Proteins were eluted with a linear gradient from 0 to 0.5 M NaCl
at a flow rate of 1 ml min
21 and fractions of 1 ml were collected.
Calpastatin activity was measured using purified human erythro-
cyte calpain prepared as reported in [22] and human acid-
denatured globin as a substrate as described earlier [23].
2.9 Identification of calpastatin species by SDS-
polyacrylamide gel electrophoresis
Calpastatin fragments were analysed as described previously
[24]. 6610
7 erythroid precursor cells cultured from 4 controls, 5
patients with mild and 5 patients with severe clinical symptoms,
respectively, were prepared and lysed as described above.
Supernatants were concentrated to 50 ml by ultrafiltration on an
Amicon centrifugation tube (MW cut off 10 kDa) and proteins
were separated on large format (16616 cm) 12% SDS-poly-
acrylamide gels. Gels were washed 6 times for 10 min each with
buffer A containing 0.1 mM EDTA and 20% methanol, to
remove SDS and subsequently were washed 3 times each for
10 min with buffer A containing 0.1 mM EDTA to remove
methanol. Gels were cut into 3 mm thick slices and proteins were
extracted from each slice by incubation with 600 ml extraction
buffer (buffer A containing 0.1 mM EDTA) in continuous and
gently shaking at room temperature for 48 hr.
2.10 Statistical analysis
Results are expressed as the mean plus standard error and the
mean plus or minus standard error. Experimental groups were
compared using the nonparametric test, with a p value of less than
0.05 indicating statistical significance.
Results
3.1 In vitro culture of erythroid precursor cells
In this study, we have initiated a biochemical characterization of
the calpain-calpastatin system in proerythroblasts derived from
cultured precursor cells of thalassaemic patients chosen and
selected as specified in Methods. We have cultivated samples
enriched for CD34
+ cells for 7 days under conditions promoting
the differentiation into erythroid precursor cells (proerythroblasts).
Purity of the cell population expanded ex vivo was analyzed by flow
cytometric detection of the erythroid specific-cell surface markers,
transferrin receptor (CD71) and glycophorin A (CD235a). More
than 90% of the produced cells expressed erythroid-specific
surface proteins (Fig. 1A). Differential determination of samples by
Wright Giemsa’s staining identified 93–95% erythroid precursor
cells at the proerythroblast stage and 2–4% at the basophilic
normoblast stage, whereas white blood cells comprised ,1% of
the samples (Fig. 1B).
Figure 1. In vitro culture of CD34
+-derived erythroid precursor
cells. A) Purity of CD34
+-derived erythroid precursor cells after
cultivation for 7 days as analyzed for a control and one thalassemic
patient by flow cytometry. Cells that express erythroid specific cell-
surface markers, glycophorin A (CD235a) and transferrin receptor
(CD71) (quadrants R1–R3), are shown as flow cytometry plot. B)
Erythroid precursor cells were stained using Wright-Giemsa’s staining.
Images were captured by a microscope digital camera system (Olympus
CH-2, magnification 10006).
doi:10.1371/journal.pone.0037133.g001
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Calpain activity was measured in cytosolic fractions obtained
from cells isolated from healthy controls and from patients with
mild and severe symptoms, as described in Methods, using the
fluorogenic substrate Ac-LLY-afc. The protease activity was
measured also in the presence of EDTA or of the synthetic
calpain inhibitor Z-LLY-fmk [20,21] or of the protease natural
inhibitor calpastatin (RNCAST300). Thus, the non-specific
activity detectable in the presence of the inhibitors has been
subtracted to the activity assayed in the presence of Ca
2+ alone.
Proteolysis of the fluorogenic substrate in the assay containing
EDTA or calpain inhibitors was poorly detected, indicating
a limited contamination by other proteases. As shown in Fig. 2,
calpain activity in the 5 controls showed a mean value of
approximately 2,500 RFU with a fluctuation of 6400 RFU. In the
cytosol from mild cases, the mean value resulted to be increased up
to 7,800 RFU with fluctuation from 5,000 to 13,000 RFU. The
complete absence of superimposed values between controls and
mild cases indicates that these differences are highly significant.
Conversely, calpain activity in cytosol from severe cases was only
15–25% higher than levels of the control and significantly lower
than in mild cases. Thus, the increase in fluorescence over the
background can be attributed to the activity of calpain present in
samples (Fig. 2).
3.3 Expression of m-calpain
Since the calpain fluorimetric assays shown in Fig. 2 were not
indicative of the level of calpain present in the samples, due to the
presence of its natural protease inhibitor, calpastatin, we have
measured the protein level of m-calpain, the protease isoform
preferentially expressed in erythrocytes [25] by immunoblotting.
As shown in Fig. 3A and B, the 80 kDa protease band,
corresponding to the calpain catalytic subunit, was more intense
in all the 5 mild cases, as compared to controls and also to the 5
severe cases. Quantification by densitometric analysis revealed
that the calpain signal detected in mild cases ranged from 2.5 to
4.5-fold significantly higher than that observed in controls and in
severe cases, 3.5 to 3.7-fold higher in respect to severe cases and
controls, respectively. The absence of the 78 and 75 kDa calpain
bands in the immunoblots suggests that these autoproteolysed
calpain forms are not accumulated in the cell and probably rapidly
removed by aggregation and further digestion [25]. Thus, these
data are in agreement with those showed in Fig. 2 and confirm
that increased calpain activity detected in mild cases are due to
a parallel increase in expression of m-calpain. This conclusion is
further supported by data showing that a direct correlation
between the amounts of protein detected with the anti-calpain
antibody and the calpain hydrolytic activity evaluated into the cells
exists (Fig. 3C).
3.4 Level of calpastatin in mild and severe cases
It was surprising that in cells from severe cases, the level of
calpain was significantly lower compared to the mild cases. To
explain this possible discrepancy, we have measured the level of
calpastatin inhibitor activity in the three cell populations. As
shown in Fig. 4A, calpastatin inhibitory activity is 34% reduced in
cytosol from mild cases and only 16% reduced in severe cases.
These observations are consistent with the level of calpain activity
detected in the cytosol of these subjects and the lower availability
of calpastatin present in mild cases can further enhance calpain
activation.
3.5 Assessment of intracellular calpain activation
Since a-spectrin II digestion by calpain has been identified in
almost all Ca
2+-loaded cells so far studied [25,26,27], the
formation and accumulation of the low Mr calpain digested a-
spectrin II generated by active calpain was evaluated by means of
Western blot using the specific anti-a-spectrin II mAb. As shown
in Fig. 5, the a-spectrin II fragment was detectable in all the three
cell populations, although at significantly different amounts. In
mild cases, the mean level of the modified spectrin resulted to be
increased up to approximately 5-fold, whereas in severe cases the
increase was approximately from 1.5- to 2-fold as compared to
controls. The amount of the digested a-spectrin II form was
thereby indicative of the extent of the different intracellular
calpain activation occurring in the three cell populations. The
presence of the digested a-spectrin II in control cells could be due
to an involvement of the cytoskeleton digestion in normal cell
function such as secretion [25,27,28,29,30]
3.6 Level of calpastatin in mild and severe cases
Since calpastatin can be digested by active calpain producing
low molecular weight forms still retaining the inhibitory capacity
corresponding to the isolated inhibitory domain
[22,24,25,26,27,31], we have then analyzed if the different
calpastatin molecular species were present in mild and severe
cases as compared to controls.
As shown in Fig. 6A, in controls the predominant calpastatin
species is the 70 kDa molecular form, accompanied by smaller
amounts of a 45–50 kDa form. In mild cases, the two calpastatin
species were largely reduced and a 34 kDa form were accumu-
lated. These data support the hypothesis that calpain activation
occurring in cells from mild cases is responsible also for the
fragmentation of calpastatin promoting the appearance of
significant amounts of the low molecular weight calpastatin forms.
In the severe cases, the high molecular weight calpastatin forms
are recovered, (Fig. 6B), thus suggesting the existence of a defence
mechanism as previously identified in animal brain and muscle
cells [26,27].
Figure 2. Assay of calpain activity. Analysis of cytosolic calpain
activity in erythroid precursor cells of samples from controls (n=5; n
indicates number of samples analyzed), b
0-thalassaemia/Hb E with mild
clinical symptoms (n=5), and b
0-thalassaemia/Hb E with severe clinical
symptoms (n=5). Calpain activity is plotted as relative fluorescence
units (RFU) per unit of GAPDH activity. The dashed lines represent the
mean of the calpain-independent substrate hydrolysis measured in the
presence of EDTA, Ca
2++ZLLY-fmk or calpastatin (see Methods). Data
are presented as the mean 6 standard error. Asterisks above the data
points indicate a significance of p,0.05.
doi:10.1371/journal.pone.0037133.g002
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Calpains are intracellular, neutral Ca
2+-dependent cysteine
proteases thought to be involved in numerous fundamental
processes essential for cell function [25]. In humans, two isoforms
(the ‘classical’ and ubiquitous m- and m-calpain) are characterized
by the 80 kDa catalytic subunit and a common regulatory 30 kDa
subunit. It should be noted that only m-calpain has been detected
in human erythrocytes [32]. Previous work has demonstrated that
erythrocyte m-calpain is not only involved in the degradation of
submembranous cytoskeleton proteins but also utilizes native as
well as heme-deprived a- and b-globin chains as substrate [33].
Although employing a relatively limited sample format by
selecting samples containing only identical mutations of b
0-
thalassaemia/Hb E disease, we have initially confirmed by
a biochemical assay that calpain activity is elevated in erythroid
precursor cells from patients with mild clinical symptoms. We have
found that not only enzyme activity is increased but also that the
amount of immunodetectable calpain protein is higher in patients
with mild clinical symptoms than those of healthy controls and
patients with severe clinical symptoms. Since activity of calpain is
strictly regulated by its inhibitor, calpastatin, and it has been
proposed that massive overactivation of calpain in erythroid
precursor cells is prevented by calpastatin [16], we have
investigated both calpastatin activity and calpastatin molecular
forms present in our samples.
Calpastatin is a protein inhibitor with high specificity for calpain
proteases [34]. It is synthesized in erythrocytes predominantly as
Figure 3. Correlation between m-calpain protein expression and activity in individual samples of normal and b
0-thalassaemia/Hb E
proerythroblasts. A) Western blot analysis of m-calpain protein expression. Immunoblots show m-calpain present in individual samples from 5
patients. B) Densitometric analysis of the m-calpain protein band. Scatter graph representing m-calpain amounts. m-calpain protein amounts were
normalized against GAPDH band intensity. Data are presented as mean 6 standard error. Asterisks above the data points indicate a significance of
p,0.05. C) Correlation between m-calpain expression and activity. Data are taken from Figure 3B and Figure 2. (%) indicates control, (#) patients
with mild clinical symptoms, and (D) patients with severe clinical symptoms.
doi:10.1371/journal.pone.0037133.g003
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type and tissue-type calpastatin (110–120 kDa) were identified in
the erythroid cell line JK-1 thus suggesting that erythroid
precursor cells can contain both forms of the inhibitor [35]. In
general, calpastatin protein amounts are much higher than those
of calpain in various cell types [36]. A balance of protein amounts
between calpain and calpastatin and/or subcellular distribution of
calpastatin has been anticipated as possible mechanism for the
regulation of calpain activity [37,38].
Alteration of the calpain/calpastatin ratio observed in cells from
mild cases can also explain the large extent of proteolytic
degradation of a-spectrin II by calpain occurring in the cell
population. The recovery of calpastatin in cells from severe cases
and the decrease in calpain protein are consistent with the lower
degree of intracellular calpain activation in these cells.
Moreover, previous studies have demonstrated that calpastatin
also serves as substrate for proteolytic degradation by calpain itself
and consequently increased calpain activation has been associated
with reduced calpastatin activity [26]. We have therefore decided
to characterize the activity of calpastatin molecular species and its
specific degradation products. By SDS-PAGE gel extraction, we
detected the activity of both native of calpastatin forms, the tissue
(110 kDa) and erythrocyte type (70 kDa). Moreover, calpastatin
activity was observed at the lower protein molecular weights of 45
and 34 kDa. Earlier studies have suggested that enhanced
formation of a 45-kDa calpastatin subunit is a result of the partial
degradation of calpastatin by intracellular calpain [39]. A previous
report has described the production of a 34-kDa calpastatin
subunit with inhibitory activity as result of a proteolytic cleavage of
the 45-kDa fragment by m-calpain in rat liver [40]. We have
observed that the activity of the 110 kDa tissue-type calpastatin
was significantly reduced when compared to the 70 kDa
erythrocyte-type calpastatin in proerythroblasts from patients with
mild clinical symptoms. In accordance with earlier observations, it
is conceivable that under conditions of elevated calpain amounts
and activity, calpain-mediated proteolysis of tissue-type calpastatin
occurs faster than degradation of the erythrocyte-type [35,39].
Additionally, we observed the accumulation of the 34-kDa
calpastatin fragment in patients with mild clinical symptoms,
whereas amounts of this fragment in the control samples were
almost negligible and slightly increased in patients with severe
clinical symptoms. As total calpastatin activity was significantly
reduced in samples from mild cases, it is therefore conceivable that
calpain-mediated degradation of calpastatin generates the active
34-kDa fragment and smaller inactive peptides as described earlier
[26].
Finally, the observed decrease in both calpain activity and
protein can be due to a higher rate of activation/inactivation
process at which calpain undergoes, causing a consumption of the
protease. This hypothesis is also supported by the higher extent of
Figure 4. Assay of total calpastatin activity. The bar graph represents calpastatin activity in the sample groups. Calpastatin activity is shown as
units of activity per 10
6 erythroid precursor cells. Asterisks above the bars indicate a significance of p,0.05.
doi:10.1371/journal.pone.0037133.g004
Figure 5. Assessment of intracellular calpain activation by
spectrin degradation. Intracellular calpain activation has been
evaluated by measuring the amount of the a-spectrin II proteolytic
fragment. Aliquots (25 mg protein) of crude extract obtained from the
three cell populations as described in Methods were submitted to 6%–
10% gradient SDS-PAGE followed by Western blotting. Nitrocellulose
membranes were probed by using the specific mAbs as described in
Methods. Bands were quantified as in Methods. Native and digested
fragment amounts of a-spectrin II were normalized against GAPDH
band intensity, utilized as an internal loading control protein. The
pictures in the upper panel are representative of the experiments
performed. Data are presented as mean 6 standard error. Asterisks
above the data points indicate a significance of p,0.05.
doi:10.1371/journal.pone.0037133.g005
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activity was detectable. The presence of high amounts of low
molecular mass calpastatin forms, produced also by active calpain
[22,26,27] is also indicative of calpain activation, whereas the
recovery in the inhibitor level in cells from severe cases is
consistent with a defence mechanism shown to operate under
conditions of prolonged alteration of Ca
2+ – homeostasis
[22,27,31].
Taken together, our results would suggest that increased calpain
protein expression under elevated intracellular calcium concen-
tration in thalassemic proerythroblasts [41] may lead to increased
calpain activity and enhances the degradation of calpastatin in
patients with mild clinical symptoms. Elevated calpain activity in
patients with mild clinical symptoms has been previously suggested
to contribute to an accelerated degradation of its committed
substrate, free a-globin chains, resulting in reduced precipitation
of globin, a lower degree of ineffective erythropoiesis and
amelioration of the pathophysiological symptoms of b-thalassae-
mia/Hb E [9,13]. However, further investigations are required to
address the mechanism by which calpain protein expression
becomes elevated in mild forms of b-thalassaemia/Hb E, whereas
it seems retaining a basal level in severe forms of b-thalassaemia/
Hb E. It can not be ruled out at present that additional proteolytic
functions contribute to the modification of disease severity [32,42].
It is also important to note that a multitude of factors including
genetic disposition and their possible interaction determining the
phenotypic variability in the clinical manifestations and physio-
logical response to genetic defects in thalassaemic diseases remains
largely to be investigated [43]. Nevertheless, this study has
demonstrated for the first time directly a possible association
between disease severity and calpain activation in thalassaemia.
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